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Abstract
Background: Sleepiness and cognitive dysfunction are recognized as prominent consequences of sleep
deprivation. Experimentally induced short-term sleep fragmentation, even in the absence of any reductions in total
sleep duration, will lead to the emergence of excessive daytime sleepiness and cognitive impairments in humans.
Tumor necrosis factor (TNF)-α has important regulatory effects on sleep, and seems to play a role in the occurrence
of excessive daytime sleepiness in children who have disrupted sleep as a result of obstructive sleep apnea, a
condition associated with prominent sleep fragmentation. The aim of this study was to examine role of the TNF-α
pathway after long-term sleep fragmentation in mice.
Methods: The effect of chronic sleep fragmentation during the sleep-predominant period on sleep architecture,
sleep latency, cognitive function, behavior, and inflammatory markers was assessed in C57BL/6 J and in mice
lacking the TNF-α receptor (double knockout mice). In addition, we also assessed the above parameters in C57BL/
6 J mice after injection of a TNF-α neutralizing antibody.
Results: Mice subjected to chronic sleep fragmentation had preserved sleep duration, sleep state distribution, and
cumulative delta frequency power, but also exhibited excessive sleepiness, altered cognitive abilities and mood
correlates, reduced cyclic AMP response element-binding protein phosphorylation and transcriptional activity, and
increased phosphodiesterase-4 expression, in the absence of AMP kinase-α phosphorylation and ATP changes.
Selective increases in cortical expression of TNF-α primarily circumscribed to neurons emerged. Consequently,
sleepiness and cognitive dysfunction were absent in TNF-α double receptor knockout mice subjected to sleep
fragmentation, and similarly, treatment with a TNF-α neutralizing antibody abrogated sleep fragmentation-induced
learning deficits and increases in sleep propensity.
Conclusions: Taken together, our findings show that recurrent arousals during sleep, as happens during sleep
apnea, induce excessive sleepiness via activation of inflammatory mechanisms, and more specifically
TNF-α-dependent pathways, despite preserved sleep duration.
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Background
Sleep fragmentation (SF), unlike prolonged sleep
deprivation, is a common consequence of many sleep
disorders in humans [1,2], of narcolepsy [3], and of sub-
optimal sleeping conditions, such as noisy environments.
A minimum period of uninterrupted sleep is essential
for optimal daytime vigilance and neurocognitive and
behavioral functions [4-6]. Cytokines such as tumor ne-
crosis factor (TNF)-α and interleukin (IL)-1beta are
multifunctional pro-inflammatory cytokines, which have
been recognized not only as crucial inflammatory media-
tors, but also as important mechanisms involved in the
regulation of sleep[7], aging and neurodegenerative dis-
eases associated with aging [8,9], and learning[10,11].
TNF-α can be synthesized and released in the brain by
both neurons and glial cells, and exerts multiple func-
tions by binding to two different TNF receptors (p55
(TNFR1) and p75 (TNFR2)), which are constitutively
expressed in the nervous system [12]. TNF-α and IL-1β
enhance slow wave sleep (SWS), and inhibition of TNF-
α or IL-1β reduces spontaneous sleep. Exogenous injec-
tion of TNF-α or IL-1β into animals and/or humans
induces sleepiness and elicits excess sleep [7], whereas
prolonged wakefulness upregulates both TNF-α and IL-
1β in the brain [7]. Interestingly, pathological concentra-
tions of TNF-α inhibit long-term potentiation (LTP), a
surrogate reporter of learning and memory in the hippo-
campus [12-16], and impair cognitive function [17].
In the brain, expression of Homer1a is increased after
sleep loss, suggesting a role for sleep in the regulation of
intracellular calcium homeostasis, particularly in protec-
tion and recovery from the calcium-pool changes
induced by the prolonged neuronal activation imposed
by extended wakefulness [18]. According to Tononi and
Cirelli, the plastic processes occurring during wakeful-
ness result in increased synaptic strength, whereas the
role of sleep is to downscale synaptic strength to a basal
level while the newly acquired information is retained.
Both environmental and pharmacological stressors upre-
gulate Homer1a mRNA in key structures involving
higher brain functions [19]. Spontaneous wakefulness
has been shown to be associated with the diffuse induc-
tion of molecular changes usually associated with LTP
[20,21], including the phosphorylation of cyclic AMP re-
sponse element-binding protein (CREB) and the induc-
tion of genes such as Arc, brain-derived neurotrophic
factor, nerve growth factor-induced gene A , Homer, and
neuronal activity-regulated pentraxin [22-24]. Type 4
cAMP phosphodiesterase (PDE)4, a PDE enzyme that
hydrolyzes cAMP, is known to play an important role in
memory processes. PDE4 inhibition increases intracellu-
lar availability of cAMP, which is known to activate the
downstream target CREB protein after activation of pro-
tein kinase A. This signaling cascade is important in the
consolidation of memory processes and synaptic plasti-
city [25-27]. Furthermore, rolipram, a selective inhibitor
of PDE4, was shown to completely reverse the amnesic
effects of MK-801 on working and reference memory
[28] via increased cAMP/CREB signaling in the hippo-
campus [29]. The sensory, motor, or cognitive activities
that occur during active wakefulness are often asso-
ciated, in a small subset of neurons, with high peak fir-
ing rates that are likely to give rise to LTP-related plastic
changes [30]. This induction of LTP-related genes during
spontaneous wakefulness can increase further if animals
are kept awake longer by gentle handling, or if they en-
gage in extensive exploration of their environment [31].
By contrast, during sleep the expression of LTP-related
genes is severely reduced or abolished [20,21,32]. Sup-
port for the notion that synaptic strength may increase
during wakefulness also comes from experiments in
humans [33]and mice [34,35] showing that brain metab-
olism, which is mostly due to synaptic activity, increases
from early to late wakefulness.
SF is one of the hallmark characteristics of sleep
apnea. Experimentally induced short-term SF, even in
the absence of any reductions in total sleep duration,
will lead to the emergence of excessive daytime sleepi-
ness and cognitive impairments in humans [4,6]. How-
ever, the vast majority of the studies aiming to unravel
the role of sleep in the homeostatic regulation of bio-
logical systems has focused on sleep deprivation [36-38],
or alternatively has used SF procedures only for short
periods [39-42]. To examine the effects of long-term SF
in mice, thereby mimicking the long-standing clinical
course of sleep apnea preceding its diagnosis, we took
advantage of a newly designed and validated device that
does not require increments in locomotion, precludes
the need for tethering or social isolation, and is not asso-
ciated with increase in corticosterone levels [43].
Methods
The experimental protocols were approved by the Insti-
tutional Animal Use and Care Committee and are in
close agreement with the National Institutes of Health
Guide in the Care and Use of Animals. All efforts were
made to minimize animal suffering and to reduce the
number of animals used.
Animals
Male C57BL/6 J mice TNF-α receptor double knock-
out mice (TNFR-KO; catalog #003243, B6;129 S-
Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J; Jackson Laborato-
ries, Bar Harbor, ME, USA), matched for age and
weight (20–25 g), were housed with a 12 hour light/
dark cycle (07.00 to 19.00 hours) at a constant
temperature (26 ±1°C), and allowed access to food and
water ad libitum.
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Sleep fragmentation exposures
The SF device used to induce SF in rodents has been
previously described [43] (catalog # Model 80390, Lafay-
ette Instruments, Lafayette, IN, USA), and employs
intermittent tactile stimulation of freely behaving mice
in a standard mouse laboratory cage, using a near-silent
motorized mechanical device. All SF procedures were
carried out for 12 hours from 07.00 to 19.00 hours dur-
ing the light period (LP).
Surgical procedure and implantation of telemetric
transmitter and electrodes
All surgical procedures were performed under sterile
conditions and general anesthesia. A telemetric transmit-
ter weighing 3.5 g (F20-EET; DSI, MN, USA), which
allows simultaneous monitoring of two biopotential
channels (temperature and locomotor activity) were
chronically implanted to record an electrencephalogram
(EEG) from the frontal area and an electromyogram
(EMG) from the superior nuchal muscle [43] .
Sleep recordings, SF, and sleep scoring were performed
as previously described [43,44]. Behavior was classified
into three different states: wake, SWS, and rapid eye
movement (REM) sleep. EEG during wake had low-
amplitude, high-frequency (desynchronized) waves. Dur-
ing wake, EMG records showed gross body movement
artifacts, and behaviorally, animals had grooming,
scratching, and orienting activity. The SWS stage was
characterized by low-frequency, high-amplitude (syn-
chronized) EEG with a considerable reduction in EMG
amplitude. REM sleep was characterized by desynchro-
nized EEG, and a drastic reduction in EMG (muscle
atonia). Sleep-related low frequency (delta) activity was
also derived from the records using bandpass filtering of
1 to 4.0 Hz. Delta power was computed offline by
Fast Fourier Transform (FFT) using SleepSign software,
Kissei Comtec Co., LTD., Nagano, Japan which was
based on 512 points corresponding to 10 second epochs,
at a sampling rate of 250 Hz, with Hanning as the win-
dow filter of FFT. The software algorithm analysis was
based on The Nyquist–Shannon sampling theorem,
which states that perfect reconstruction of a signal is
possible when the sampling frequency is greater than
twice the maximum frequency of the signal being
sampled. Those SWS epochs that showed movement
artifacts were excluded when computing delta power, be-
cause EEG signals are especially sensitive to movement,
with the resulting artifact specifically enhancing signals
in the delta band. SWS latency was calculated as the
time taken from each arousal episode to the first epoch
of SWS.
For the neutralizing antibody studies (TNF-α antibody
(Ab) + SF), we gave the C57BL/6 J mice an intraperitoneal
injection of either vehicle (saline) or TNF-neutralizing
antibody (clone TN3-19; eBiosciences, 100 μg per mouse/
day) 10 minutes before starting the SF procedures) [45].
Behavioral testing
The Morris water maze was used to assess spatial refer-
ence learning and memory, and working memory. The
maze protocol is similar to that described by Morris [46],
with modifications for mice. Briefly, a standard place-
training reference memory task was conducted on mice in
the water maze after exposure to 15 days of SF or saline.
Place learning was then assessed over six consecutive days
using a spaced training regimen that has been found to
produce optimal learning in mice [47]. Maze performance
was recorded by a video camera suspended above the
maze and interfaced with a video tracking system (HVS
Imaging, Hampton, London, UK). The performance in the
water maze was assessed using mean escape latencies and
swim distance. Retention tests were carried out 15 days
after acquisition of the task as previously described [48].
For the elevated plus maze (EPM), which is a measure of
anxiety, mice were placed in the center of the maze facing
a closed arm, and allowed to explore for 10 minutes in iso-
lation. Data acquisition and analysis were automatically
processed (Noldus Ethovision Software; Leesburg, VA).
The percentage time spent in the open, the number of en-
tries into the closed arms, and the time spent in the center
were analyzed. In the forced swimming test (FST), a meas-
ure of murine depression and anhedonia, mice were indi-
vidually forced to swim for 6 minutes on two consecutive
days in an open cylindrical container (diameter 140 mm;
temperature 25± 1°C). Mice were marked as immobile if
they performed the minimal amount of work required to
float for at least 1 second as previously described [49-51].
Of note, the mice were returned to the SF cages immedi-
ately after the behavior tests (<60 minutes), so that there
was no recovery phase in these mice.
Measurement of ATP levels
Cortical tissues were snap-frozen in liquid N2 within 20
seconds and were pulverized on LN2 for nuclear acid ex-
traction using ice-cold 5% trichloroacetic acid (TCA). The
mixture was sonicated with a probe sonicator for 10 pulses
and separated by centrifugation at 10,000 g and 4°C for 15
minutes. The supernatant was collected and neutralized
with Tris buffer (1 mol/L, pH 7.8). ATP levels were then
measured using a commercial kit )ATP Bioluminescence
Assay Kit CLS II; Roche Applied Science, Indianapolis, IN,
USA). Protein concentrations in the supernatant were
determined using a protein assay kit (Bio-Rad Dc; Bio-Rad,
Hercules, CA, USA) to normalize ATP levels.
Assessment of AMP kinase α activation
Snap-frozen cortical tissues were pulverized on liquid N2
and immediately homogenized in 1% SDS preheated to
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92°C. The homogenate was separated by centrifugation
at 14,000 g for 15 minutes, and the supernatant contain-
ing total cellular proteins was collected. This method
has been shown previously to effectively inhibit activa-
tion of phosphorylation and dephosphorylation pro-
cesses associated with many routine protein preparation
protocols [52,53]. The protein concentration was deter-
mined (Microplate BCA Protein Assay Kit; Pierce Bio-
technology, Rockford, IL, USA) and samples were then
subjected to western blotting analysis for AMP-activated
protein kinase (AMPK) activation. The same blot was
used for detection of the phospho-AMPK-α (anti-
pAMPKα; Cell Signaling Technology, Danvers, MA,
USA) and the total AMPK-α (anti-AMPKα; Cell Signal-
ing Technology) and positive signals were visualized
with enhanced chemiluminescence.
CREB DNA binding assay
Nuclear extracts from hippocampal tissues harvested
from mice exposed to SF or control sleep conditions
were prepared (Nuclear Extract Kit; cat. # 40010; Active
Motif, Carlsbad CA, USA), in accordance with the man-
ufacturer’s instructions, using a dounce homogenizer.
For the DNA binding assays, six animals per condition
were studied. CREB nuclear binding was assessed
using (Trans-AM phospho-CREB activation Assay
Kit; cat. #43096; Active Motif, Carlsbad, CA). This
enzyme-linked immunosorbent assay employs an anti-
body that selectively recognizes the phosphorylated epi-
tope of CREB when the latter is specifically bound to a
specific oligonucleotide coated onto a 96-well plate.
Specificity of the binding was further monitored by
competition with free wild-type and mutated oligonu-
cleotides. Samples were assessed by a spectrophotom-
eter at 450 nm.
Quantitative real-time PCR
The mRNA expression (TNF-α, IL-1, IL-6, TNFR1,
TNFR2, and phosphodiesterase 4) was determined by
quantitative RT-PCR using commercially available spe-
cific primers.
TNF-α ELISA
TNF-α brain cortical levels were measured in triplicate
using a commercially available ELISA assay in accord-
ance with the manufacturer’s instructions (Mouse TNF-
alpha ELISA Kit, OptEIA™; BD Biosciences). This
method has a minimum detection level of 0.25 pg/ml
with intra-assay and inter-assay coefficients of variabil-
ity of 7.4% and 7.8% respectively, and a dynamic linear
range of 2.2 to 2,500 pg/ml. Assays were deemed
acceptable if triplicate values were within 10% of each
other.
Immunohistochemistry
Anesthetized mice were perfused transcardially with 0.9%
NaCl followed by 4% formalin, then the brains were
removed, fixed in 4% formalin, and cryoprotected with
30% sucrose. Coronal sections (40 um) were incubated in
0.3% H2O2 for 30 minutes, washed in PBS, and blocked
with a buffer of PBS containing 0.4% Triton X-100, 0.5%
tyramide signal amplification (TSA) blocking reagent (New
England Nuclear Life Science Products, Boston, MA, USA)
containing 10% normal goat serum (NGS; Vector Labora-
tories, Burlingame, CA, USA) for 1 hour. Sections were
then serially incubated with either TNF-α (cat # RM90115
1:1,000; Invitrogen Corp., Carlsbad, CA, USA) or pCREB
antibody (1:1000; Cell Signaling Technology, Beverly, MA,
USA) at 40 C for 48 hours with a biotinylated anti-rabbit
antibody (1:600 in the PBS/0.5% TSA/10% NGS blocking
reagent described above) (Vectastain Elite ABC kit, Vector
Laboratories), and then with streptavidin-horseradish per-
oxidase (diluted 1:100 in the blocking reagent as before)
followed by tetramethyl rhodamine tyramide diluted 1:50
for 2 minutes (Perkin Elmer Life Sciences). Sections
were subsequently incubated with serum raised against the
neuronal marker Neu-N (1:1000; Chemicon, Temecula,
CA), followed by a biotinylated anti-rat antibody (1:200 l
Vectastain Elite ABC Kit), and by fluorescein tyramide re-
agent (1:50) for 3 minutes (Perkin Elmer Life Sciences).
Sections were then washed in PBS and mounted onto glass
slides. In general, 20 sections/animal were visualized using
both fluorescent and confocal microscopes.
Data analysis
To elucidate the nature of identified interactions be-
tween control baseline sleep characteristics and those
emerging after 15 days of SF in C57BL/6 J mice and
TNF-α receptor knockout mice, the data were analyzed
by one-way repeated-measures ANOVA. First, overall
statistical significance between the treatment groups
(baseline and SF) was determined for the 24-hour
period, followed by post-hoc Tukey tests, as needed.
Delta power during SWS, wake episodes, and the latency
of SWS after each episode of wake were also treated
with similar statistical approaches. Similar statistical
approaches were used to compare the entire training
period between the treatment groups. In addition, two-
way repeated measures ANOVA were used to analyze
each trial blocks, followed by post hoc Tukey tests. The
same statistical approaches were used to compare probe
trial, reference memory, EPM, and FST. For all compari-
sons, P< 0.05 was considered significant. For behavioral
test assessments, all the experimental conditions, the
data were divided into six blocks (of 3 trials/day). We
used a multivariate MANOVA model (SPSS software
version 11; SPSS Inc., Chicago, IL, USA) that included
latency, path length, and swim speed, and two between-
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group factors: 1) Groups (four levels): Sleep control
(SC)-C57BL6/J, SC-TNF-KO and TNF-KO mice exposed
to 15 days SF (SF-TNF-KO) ; and 2) condition (two
levels): SC or SF. All F statistics are reported using Pil-
lai’s Trace. The interaction of three different factors
(time, condition, and group) were determined using this
mixed-model repeated-measures MANOVA. The bio-
chemical assays were analyzed using one-way ANOVA.
Results
Sleep architecture and behavioral changes after 15 days
of sleep fragmentation in C57BL/6 J mice
Measurements of wake and sleep
Overall analysis of the polygraphic data for a period of
24 hours (n= 12/group) showed significant differences
between baseline and SF (P< 0.001), indicating that
SF had influenced state (wake, SWS, and REM sleep).
EEG monitoring during the 12-hour LP (07.00 to
19.00 hours) showed that the C57BL6/J mice were awake
for 38.52 ± 4.11% of the time; after 15 days of SF, they
spent 42.66 ± 0.85% of the time awake. Analysis of SWS
and REM sleep during LP showed that the animals spent
52.81 ±9.90% and 8.68 ±1.73% of the time in SWS and
REM sleep respectively, during baseline, which decreased
to 50.39 ±0.86% and 6.9 ± 0.33%, respectively, after 15 days
of SF. During the dark period (DP), there was no signifi-
cant variation in wake, SWS, or REM sleep in animals
subjected to 15 days SF, who had values of 58.27 ± 0.78,
36.9± 0.66 and 4.83± 0.13%, respectively, compared with
baseline values of 64.59 ± 3.66, 32.01 ± 3.51 and
3.4 ± 0.35% (Figure 1A–C). There was also no change in
total time spent (24 hours) in wake, SWS, and REM
sleep after 15 days SF (50.46 ±0.78, 43.64 ±0.70 and
5.89 ±0.18% respectively) compared with baseline
(51.55 ±3.26, 42.41 ±3.35 and 6.03 ±0.23%) (Figure 1A–C).
Wake episodes, delta powe,r and SWS latencies
Mice subjected to SF for 15 days maintained total
sleep duration, with values comparable with the base-
line values, and also globally maintained sleep state
Figure 1 Circadian sleep characteristics and sleep state distribution during baseline conditions (solid line) and after 15 days of sleep
fragmentation (dotted line) in mice. (A–C) There was an absence of significant alterations in sleep architecture, despite (D) continuing
successful induction of episodic awakenings. (E) No changes in delta frequency power of the EEG emerged; but there were (F) marked
reductions in mean sleep latency. (BL) baseline vs. sleep fragmentation (SF); *P< 0.0001; n = 12/group). Shaded regions represent dark phase of
the circadian cycle (07.00 to 19.00 hours).
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distribution and duration, despite ongoing recurring
awakenings induced by the SF procedures. After 15 days
of SF, there was a significant increase in wake episodes
during LP (39.58 ±1.77 per 2 hours) compared with
baseline (13.38 ±2.08 episodes per 2 hours) (F= 40.02, P
< 0.001] indicating intermittent arousals (Figure 1D).
However, there was no difference in the frequency of
wake episodes during the DP after cessation of SF proce-
dures, with 15.42 ±1.75 episodes per 2 hours. A signifi-
cant increase in wake episodes after 15 days of SF was
therefore recorded for the 24 hour period (mean for 24-
hour period: 27.15 ±0.81 per 2 hours) compared with
baseline (13.62 ±1.76 per 2 hours) (Figure 1D).
Delta power during SWS of the EEG remained un-
changed after SF (192.88 ±25.09 μV2 at baseline vs.
189.28 ±25.85 μV2 after SF; Figure 1E), even though delta
power is increased during sustained wakefulness, is highest
during the initial cycles of SWS, decreases across the bio-
logical night, is maximally expressed in frontal derivations,
and shows rebound effects after sleep deprivation, thereby
accounting for its extensive use as a marker of homeostatic
sleep regulation [54-56]. After cessation of SF procedures,
there were no differences in delta power during the DP,
and no changes in delta power emerged across 24 hours
(Figure 1E). However, as previously shown [48], SF-
exposed mice exhibited markedly reduced SWS latencies
[57] and theta EEG frequency waking activity [58], both of
which are strong indicators of the presence of excessive
sleepiness (Figure 1F). Overall analysis of the data for a
period of 24 hours found significant changes between base-
line and SF (P< 0.001), indicating that SF had significant
effects on SWS latency. The latency to SWS was signifi-
cantly reduced throughout the LP during the SF proce-
dures. On average, the control animals had a latency of
368.16 ±72.73 seconds to SWS at baseline, compared with
73.14 ±2.86 seconds on day 15 (P< 0.0001), indicating pro-
gressive increases in sleep propensity. Immediately after
cessation of SF procedure, the latency to SWS during DP
Figure 2 Spatial learning performance. (A) (a, b) Mean path lengths (cm) and latencies (seconds) to locate the target platform during place
training, (c) swim speed and (d) mean percentage time in the target quadrant during probe trials after completion of water maze testing, with
(e) path lengths and (f) latencies during assessment of spatial task retention in the water maze in mice exposed to 15 days of sleep
fragmentation and those maintained in control sleep conditions (n = 18 per group; *P<0.0001). (B) Mice exposed to sleep fragmentation
(a, b) showed less immobility during the forced swim test, (c) performed significantly more entries into the closed arms, and (d) spent
significantly less time in the open arms of the elevated plus maze compared with mice having control sleep conditions (n = 18/group;
* P<0.002).
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had a tendency to return to baseline levels. However, for a
total period of 24 hours (from 0700 to 0700 hours the next
day), the latency to SWS remained significantly lower after
SF (230.47 ±8.88 seconds) compared with baseline (443.87
±82.06 seconds (F=18.823, P< 0.001) (Figure 1F). Quiet
wake theta activity during the DP was significantly
increased after SF (F =15.906, P< 0.003).
Spatial learning performance
On a standard place-discrimination task, C57BL6/J mice
exposed to 15 days of SF (SF-C57BL6/J) exhibited longer la-
tencies and path-lengths to locate the hidden platform
compared with control mice (SC-C57BL6/J), (n=18 per ex-
perimental condition, Figure 2Aa, 2Ab). Overall analysis of
the entire trial blocks showed significant differences be-
tween the SF and control sleep treatment groups for latency
(F=24.291; P< 0.001) and path length, (F=17.785; P<
0.001), indicating that SF adversely affected task
performance. Significant differences in latencies were seen
during blocks 2 (F=7.240; P< 0.021), 3 (F=24.426; P
< 0.001), 4 (F=20.290; P< 0.001), 5 (F=8.401; P< 0.014)
and 6 (F=7.924; P< 0.017). There were no significant dif-
ferences in block 1. Repeated measures ANOVA showed
significant differences in path lengths during blocks 2
(F=10.226; P<0.008), 3 (F=15.25; P< 0.004), 4
(F=14.483; P< 0.003), 5 (F=12.496; P< 0.005) and 6
(F=32.024; P< 0.001), with no significant differences in
block 1. There were no significant differences in swim
speed (Figure 2Ac). In the probe-trial test, one-way
ANOVA showed a significant effect of treatment [SF vs.
SC: F=76.017; P< 0.001). The magnitude of impairment
was greatest in SF-C57BL6/J mice (Figure 2Ad). In the
reference memory tests, SF-C57BL6/J mice exhibited sig-
nificant deficits in memory retention (Figure 2Ae, 2Af) in
both latency (F=11.662; P< 0.006) and path length
(F=17.696; P< 0.001).
Figure 3 Effects on cyclic AMP response element-binding protein (CREB). (A) Phosphorylated CREB expression (red fluorescence) and NeuN
(green fluorescence) in hippocampus of a representative animal exposed to sleep fragmentation (SF) for 15 days and a control (n = 3). Right
panel shows merged images. (B) Transcriptional CREB activity in untrained mice and in mice trained in the spatial task water maze (both exposed
to SF for 15 days) compared with trained and untrained non-SF controls (P<0.01; n = 5/group). (C) Time course of phosphodiesterase (PDE) 4
gene expression in cortex of mice exposed to SF (P<0.01 for all time points; n = 6).
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Forced swim test
SF-C57BL6/J mice had significantly longer periods of
immobility during the last 4 minutes of the FST
(F = 24.951; P< 0.001) and a significantly higher per-
centage of time spent immobile (F = 22.951; P
< 0.001) compared with the SC-C57BL6/J sleep con-
trols (Figure 2Ba and 2Bb).
Elevated plus maze
There were significant differences between SF-
C57BL6/J mice and controls in in the percentage of
time spent in the open arm (F = 89.25; P< 0.001)
and in the number of entries into the closed arm
(F = 53.16; P< 0.001) (Figure 2Bc, 2Bd).
CREB transcription, phosphodiesterase-4 and ATP levels
The SF-induced cognitive and behavioral alterations
were accompanied by reduced CREB phosphorylation
in hippocampus (Figure 3A) and reduced CREB tran-
scriptional activity. Similarly, CREB transcriptional
activity in the hippocampus was markedly reduced
before and after spatial task training (P< 0.01)
(Figure 3B). Furthermore, increased expression of
phosphodiesterase-4 was seen after SF (Figure 3C).
However, there was no alteration in ATP levels
(Figure 4A) andAMP kinase-α phosphorylation levels
(Figure 4B) after SF, and Homer1a gene expression
remained unchanged (Figure 4C).
Th1 cytokines in cortex
We examined changes in the expression of Th1
cytokines in the frontotemporal cortex. These experi-
ments showed not only temporally dependent
changes in gene expression of TNF-α (fold increase
2.23 ±0.25; F = 7.639; P< 0.004) (Figure 5A) and
TNFR1a gene expression (fold increase 2.82 ±0.24;
F = 14.312; P< 0.0001) but also in protein levels
(88.30 ±39.42 in controls vs. 523.71 ±45.48 after
15 days of SF; F = 31.05; P< 0.001) (Figure 5B), the
latter appearing to be preferentially localized in neu-
rons within the cortex (Figure 5C). By contrast, no
changes occurred in the gene expression of other
cytokines, such as IL-1β and IL-6 (Figure 5).
Figure 4 Effect of 15 days of sleep fragmentation (SF) on energy metabolism in the cortex. (A) ATP levels in cortical tissues from mice
with or without SF; there was no significant difference between the groups. (n = 4/group) (B) Representative western blots showing the lack of
-activated protein kinase (AMPK)α phosphorylation in the same tissues. E10 epithelial cells exposed to 0.2% O2 for 24 hours were used as a
positive control (+) for phospho- (p)AMPK. (C) Homer1a expression remains unaltered over the course of SF (n = 6/time point).
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Sleep architecture and behavioral changes in tumor
necrosis factor-α receptor knockout mice after 15 days of
sleep fragmentation
Measurements of wake and sleep
EEG monitoring of TNFR-KO mice during 12 hours of
LP showed that they were awake for 34.71 ± 1.14% of the
time without SF, which increased to 42.66 ± 0.85% after
15 days of SF (P< 0.05). During DP, these percentage were
62.13±0.81% and 56.56±0.74%, respectively (P< 0.05).
The percentage of time the TNFR-KO mice spent in SWS
was 58.1± 1.07% before SF and 56.09±1.13 after 15 days of
SF (P< 0.05) for LP, and 34.64±0.87% and 36.9± 0.66% for
DP (P< 0.05). The time spent in REM was 7.68±0.77% be-
fore SF and 6.6± 0.44% after SF during LP, and 3.47±0.88%
and 4.83±0.13, respectively, during DP (p< 0.05). There
were no changes in time spent in wake, SWS and REM
sleep during the 24 hour period. After 15 days of SF,
SWS latency was markedly reduced in the wild-type
Figure 5 (A) Time course of tumor necrosis factor (TNF)-α, TNF receptors, interleukin (IL)-1, and IL-6 gene expression in cortex of
miceexposed to SF (*P<0.01; n = 6). (B) TNF-α protein concentrations in cortex of mice exposed to sleep fragmentation (SF) and controls
(*P<0.01). (C) Immunofluorescence photomicrographs in frontal cortex of two representative mice exposed to SF for 15 days and controls(n = 4),
showing TNF-α immunoreactivity (red) and NeuN (green). Thee was an intense increase in TNF-α expression in neurons, although thesource of
such immunoreactivity might also be derived from other cellular sources (for example, microglia) or from the circulation viablood–brain barrier
transport (see text).
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controls compared with the TNFR-KO mice (−46.68
±16.80% and +49.73 ±12.32, repectively; F=18.823, P
< 0.001) (Figure 6A). On day 15. the percentage of delta
frequency during DP was non-significant in C57BL/6 J and
TNFR-KO. Although the KO mice exhibited significantly
higher absolute delta power than the C57BL/6 J mice [P
< 0.001), the percentage change from baseline mean
showed only a trend towards increase in delta.
Spatial learning performance
On a standard place discrimination task, a new group of
C57BL6/J mice exposed to 15 days of SF (SF-C57BL6/J)
exhibited longer latencies and path lengths to locate
the hidden platform compared with the sleep controls
(SC- C57BL6/J) or the SC-TNFR-KO or SF-TNF-KO
mice (that is, without and with SF, respectively)
(Figure 6Da, 6Db). Overall latency analysis for the
entire trial blocks showed significant changes between
the different treatment groups for latency (F= 6.817;
P< 0.001) and path length, (F= 8.192; P< 0.001), indi-
cating that SF adversely affected task performance for
C57BL6/J mice only. Significant differences in latencies
were seen during blocks 2 (F= 3.519; P< 0.003), 3
(F= 8.39; P< 0.001), 4 [F = 3.35; P< 0.03) and 6
(F= 20.14; P< 0.001). There were no significant differ-
ences in blocks 1 or 5. Repeated measures ANOVA
showed significant differences in path lengths during
block 6 (F= 38.60; P< 0.001), with no significant differ-
ences in other blocks. In the reference memory tests,
SF-C57BL6/J mice exhibited significant deficits in
Figure 6 Changes in sleep patterns in mice after sleep fragmentation (SF). (A) Changes in mean sleep latency after 15 days of sleep
fragmentation in 57BL6/J and tumor necrosis factor receptor (TNFR) knockout mice when compared with corresponding controls (n = 6;
P<0.001). (B) Changes in mean slow wave sleep latency during the circadian cycle in mice exposed to SF for 15 days (open circles) and treated
with vehicle (grey line) or TNF-α neutralizing antibodies (dotted line) and mice under control sleep conditions. (*P<0.01; n = 7/group).
(C) Increases in theta frequency during quiet waking in C57BL/6 J mice, indicating = increased sleepiness after SF. (D) Mean latencies (seconds)
and path lengths (cm) to locate the target platform during (a, b) place training, (c, d) reference memory after training, and (e, f) immobility in
the forced swim test in C57BL6/J and TNFR knockout mice exposed to SF or control sleep conditions (*P<0.01; n = 12/group). (E) Mean latencies
(seconds) and path lengths (cm) to locate the target platform during place training in mice exposed to SF or control sleep conditions, and
treated with vehicle or TNF-α neutralizing antibodies. (*P<0.01; n = 12/group).
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memory retention in both latency (F= 7.943; P< 0.001)
and path length (F= 1.657; P< 0.05). However, the SF-
TNF-KO mice performed similarly to sleep controls
(Figure 6Dc,e 6Dd). Repeated measures MANOVA with
latency, groups, and conditions (F= 74.61; P< 0.0001)
showed that SC TNF KO and SC C57BL6/J mice
required significantly less time than their SF littermates
to find the hidden platform in a Morris water maze
(Figure 6Da); Repeated measures MANOVA with path
length, groups, and conditions (F= 73.79; P< 0.0001)
indicated that as the training progressed, the SC TNF
KO and SC C57BL6/J mice reached the hidden platform
and covered the shortest distance compared with their
littermates exposed to SF in a Morris water maze
(Figure 6Db).
Forced swim test and elevated plus maze
SF- C57BL6/J mice had significantly longer periods
of immobility during the last 4 minutes of the FST
(F= 3.73; P< 0.03) compared with all other treatment
groups, including SF-TNF-KO mice (Figure 6De). Simi-
larly, there were significant differences in the percentage
of time SF- C57BL6/J mice spent in the open arm
(F= 32.57; P< 0.001) (Figure 6Df) compared with the
other three groups.
Sleep architecture and behavioral changes after 15 days
of treatment with a tumor necrosis factor-α neutralizing
antibody
A 24-hour EEG analysis of mice injected with saline and
subjected to SF for 15 days found comparable results to
that of C57BL6/J mice subjected to SF alone (data not
included). These mice were awake for similar lengths of
time at baseline (34.53 ±2.62%) and after 15 days of
TNF-α Ab+ SF (34.83 ±0.39%), and the difference was
not significant (P< 0.05). During the 12 hours of LP, un-
treated mice spent 57.27 ±2.7% of the time in SWS,
which reduced significantly after 15 days of TNF-α Ab+
SF (53.88 ±1.27%) (P< 0.02).A similar trend was also
seen for REM sleep (8.19 ± 0.56% with saline vs 7.28
±2.15% in TNF-α Ab+ SF). There was no significant dif-
ference in SWS latencies between saline (−86.857
±21.45%) and TNF-α Ab+ SF (−96.53 ±18.9%) mice on
day 1 during LP. On day 15 SF, the percentage difference
in SWS latency was reduced in saline-treated mice
(−223.84 ±35.09%) compared with mice treated with
TNF-α Ab+ SF (−21.39 ±18.19%, P< 0.001) (Figure 6B),
indicating that TNF-α Ab injection prevented the SF-
associated excessive sleepiness. During DP, immediately
after cessation of the SF procedure, the latency to
SWS showed a tendency to return to baseline levels
(Figure 6B). On day 15, the percentage difference in
SWS latency was further reduced in saline mice
(−223.84 ±35.09%) compared with TNF-α Ab+SF
(−21.39 ± 18.19%) (P< 0.001), indicating that TNF-α Ab
injection prevented the SF-associated excessive sleepi-
ness. Overall comparison of theta power during quiet
wakefulness, a marker of sleepiness, showed a significant
increase in C57BL/6 J after 15 days of SF (F=1.450; P<
0.039) (Figure 6C). There was an increase in theta power
during both LP and DP after 15 days of SF in the C57BL/
6 J mice only (Figure 6C). Such changes were not seen in
either the TNFR-KO or TNF-α-Ab injection groups after
SF (Figure 6C).
Retention after TNF-α neutralizing antibody injection
In the reference memory tests, SF-C57BL6/J mice injected
with vehicle (saline) exhibited significant deficits in mem-
ory retention (Figure 2E) in both latency (F=7.033; P<
0.001) and path length (F=3.743; P< 0.016) compared
with all the other groups, indicating that TNF-α Ab injec-
tion prevented SF-associated behavioral deficits.
Discussion
In this study, we aimed to investigate the effects of SF
on mice, and found that SF mimicking the recurrent
arousals associated with sleep apnea induces both
increased sleepiness and neurocognitive deficits. In
addition, we sought to investigate the role of the TNF-α
mediated pathway in SF and its relationship to measures
of sleep architecture and cognitive behavior. In healthy
people, serum inflammatory markers have been asso-
ciated with abnormal sleep architecture [59]. Patients
with obstructive sleep apnea show significant increases
in serum levels of TNF-α, IL-1β, and IL-6 [60-64]. Be-
cause there is a scarcity of data on the association be-
tween EEG arousals and inflammation in patients with
obstructive sleep apnea (OSA), the role of cytokines in
disrupting the architecture of sleep will need further in-
vestigation. Of note, a study by Yue et al. [65] suggested
that TNF-R1, but not TNF-α, is associated with arousals
during sleep in patients with OSA.
Depressive and anxiety symptoms are common in
patients with OSA [66-68], and in the present study,
similar symptoms were reproduced in the model of
chronic SF, suggesting that the recurrent arousals play a
role in these symptoms. The EPM is the most frequently
used apparatus for assessing anxiety-like behaviors in
animals, [69,70] because it enables researchers to ob-
serve the conflict between two innate rodent behaviors:
the avoidance of open space exposure, conflicting with
the tendency to explore novel environments [70]. When
placed in the EPM, naive mice will by nature tend to ex-
plore the open arms despite their natural fear of heights
and open spaces. In the present study, our results fur-
ther imply that SF modifies anxiety-like behaviors in
C57BL/6 J mice.
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Sleep fragmentation and bioenergetics in brain
We found that, in contrast to SD, SF does not curtail
sleep duration and also does not induce reductions in
ATP or intracellular energy sources, as evidenced by the
absence of AMPK phosphorylation after SF. However,
the SF-induced cognitive and behavioral alterations were
associated with reduced CREB phosphorylation and
transcriptional activity in the hippocampus, and with
increased expression of PDE4. Because sleep deprivation
has been associated with reduced brain ATP levels and
increased phosphorylation of AMPK [71-76], and with
induced expression of Homer1a [77], we further sought
to determine whether such changes in brain bioenerget-
ics and gene expression would account for the SF-
induced cognitive and behavioral phenotypes. ATP levels
were unaltered by SF, and no evidence for increased
AMP kinase-α phosphorylation or Homer1a expression
occurred. This clearly showed that altered cellular bio-
energetics did not underlie any of the phenotypic fea-
tures associated with SF, namely, increased sleep
propensity and neurobehavioral and cognitive dysfunc-
tion. Although the mechanistic link between SF and the
putatively reduced bioavailability of cAMP will have to
await further exploration, the now compellingly estab-
lished role of CREB transcription in memory and learn-
ing definitely suggests that these pathways will be
disrupted by upstream increases in TNF-α activity.
In the present study, we found that mice that are peri-
odically awakened during their sleep period exhibit sus-
tained increases in sleep propensity in the presence of
globally preserved sleep patterns and duration. Indeed,
sustained implementation of SF results in normalization
of the total duration of sleep and waking, and in delta
power. However, preserved sleep duration in the context
of chronic SF is not accompanied by normal sleep laten-
cies, thereby indicating increased sleepiness in the ab-
sence of sleep curtailment. This finding is further
corroborated by the increases in theta frequency during
quiet waking periods during the DP interval. In other
words, normalization after long-term SF of the com-
monly used and widely accepted standard measures of
sleep integrity did not abrogate the increases in sleepi-
ness, suggesting that perturbations in sleep continuity
play a crucial role in the maintenance of wake drive and
of wake-related cognitive, mood, and behavioral tasks.
Sleep fragmentation increases TNF-α in brain
Based on previous evidence suggesting that TNF-α has
important regulatory effects on sleep, and that TNF-α
plays a role in the occurrence of excessive daytime
sleepiness in children who have disrupted sleep as a re-
sult of OSA, a condition associated with prominent SF
[78-82], we explored several Th1 cytokines. However, it
should be noted that a recent study in adults with sleep
apnea failed to identify an association between polysom-
nographic variables and serum TNF-α levels, even
though the frequency of respiratory-induced arousals
was associated with the concentrations of soluble
TNFR1 in these patients [65]. Of the Th1 cytokines
explored in this study, only increases in TNF-α were
seen. Concordant with such findings, we then subjected
TNFR-KO to SF, which elicited similar increases in cor-
tical TNF-α tissue levels (data not shown); however,
these were not accompanied by any significant changes
in sleep propensity or in cognitive function. As a corol-
lary to such findings, the source of TNF-α was not iden-
tified, and could originate from multiple sources, such as
microglia, neurons, or even from the peripheral circula-
tion via regulated transporters in the blood–brain barrier
[83,84]. Indeed, systemic treatment of C57BL6/J mice
with a neutralizing TNF-α antibody during the course of
SF also prevented SF-induced increases in sleepiness and
cognitive deficits. Thus, although SF probably activated
Figure 7 Putative schematic diagram linking sleep
fragmentation (SF) to increased activation of pathways
medicated by tumor necrosis factor (TNF-α) and those
mediated by NADPH oxidase (see main text and Nair et al [48]
for more details).
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sleep homeostatic responses that ultimately resulted in
preserved overall sleep duration and characteristics, a re-
lease occurs of biological mediators with somnogenic
properties, such as TNF-α, and this is accompanied by
detrimental effects on hippocampal task performance,
similar to those seen after sleep deprivation [85,86]. We
further summarize that these behavioral changes could
also reflect altered cAMP signaling, particularly consid-
ering the increased expression levels of PDE4 that occur
after prolonged SF and the reductions in phosphorylated
CREB in the cortex and hippocampus of SF-exposed
mice [87]. The chronic SF-induced phenotype is also
reminiscent of the anxiety-like behaviors induced by dis-
rupted sleep patterns in the context of light exposure
during sleep [88].
Although these findings are essentially confirmatory of
our previous study [48], we further expanded the scope
of this work in an attempt to unravel the potential
mechanisms underlying sleepiness in this model, because
genetic ablation of NADPH oxidase prevented cognitive
deficits but failed to abrogate the reductions in SWS la-
tencies [48]. We now propose that SF induces sleepiness
via initial and rather selective activation of TNF-α path-
ways, which then will activate an NADPH-dependent
oxidative stress cascade that will ultimately lead to cog-
nitive dysfunction along with anxiety-like behaviors and
depression (Figure 7).
Conclusions
A major challenge in the field of sleep research has been
to determine how sleep disruptions resulting from an
extensive list of perturbations included in everyday liv-
ing, or those induced by illnesses such as sleep apnea,
can affect cognitive function and mood. The findings
presented here define a crucial role for TNF-α in this
context, and further support the link between sleep and
immunity [89], even in the absence of sleep curtailment
or ATP deficits [90]. Our data suggest that if compounds
can be developed to block the activity or expression of
TNF-α, or to selectively target TNF-α pathways in brain
structures, they may prove useful in the treatment of the
cognitive and mood effects of sleep disruption.
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